摘要
目的 探讨对体质量超标2型糖尿病患者采取利拉鲁肽联合二甲双胍治疗的临床分析。方法 选取2019年5月至2020年5月在辽宁省中国医科大学附属盛京医院大连医院内分泌科的80例体质量超标2型糖尿病患者,按照治疗方法的不同分组。其中对照组40例体质量超标2型糖尿病采用给予标准剂量甘精胰岛素组进行干预治疗;试验组40例体质量超标2型糖尿病患者采取利拉鲁肽联合二甲双胍治疗。比较两组患者接受治疗后的空腹胰岛素,餐后2 h胰岛素以及空腹C肽。比较两组患者接受治疗后糖尿病临床疗效评分、临床心理治疗功能评分、临床安全功能评分。结果 试验组患者接受治疗后空腹胰岛素、餐后2 h胰岛素以及空腹C肽高于对照组患者,差异有统计学意义(P <0.05)。试验组患者接受治疗后糖尿病临床疗效评分、临床心理治疗功能评分、临床安全功能评分优于对照组患者,差异有统计学意义(P <0.05)。结论 对体质量超标2型糖尿病来说,采取利拉鲁肽联合二甲双胍治疗的临床效果较好,可以有效改善体质量超标2型糖尿病情况,故对体质量超标2型糖尿病应采取利拉鲁肽联合二甲双胍治疗。
Objective To explore the clinical analysis of Lilalutide combined with metformin in the treatment of type 2 diabetes patients with body mass exceeding the standard.Methods From May 2019 to May 2020,80 patients with type 2 diabetes whose body mass exceeded the standard in the Department of Endocrinology,Dalian Hospital,Shengjing Hospital,China Medical University,Liaoning province,were selected and grouped according to different treatment methods.In the control group,40 patients with type 2 diabetes whose body mass exceeded the standard were given standard dose insulin glargine for intervention treatment;In the test group,40 patients with type 2 diabetes whose body mass exceeded the standard were treated with liraglutide and metformin.The fasting insulin,insulin 2 hours after meal and fasting C-peptide were compared between the two groups.The scores of diabetes efficacy,psychotherapy efficacy and safety function were compared between the two groups.Results The fasting insulin,2h postprandial insulin and fasting C-peptide in the test group were significantly higher than those in the control group(P<0.05).After treatment,the scores of diabetes efficacy,psychotherapy efficacy and safety function in the test group were better than those in the control group(P<0.05).Conclusion For type 2 diabetes with excess body weight,the clinical effect of Lilalutide combined with metformin is better,which can effectively improve the situation of type 2 diabetes with excess body weight.Therefore,Lilalutide combined with metformin should be used for type 2 diabetes with excess body weight.
作者
杨威
YANG Wei(Department of Endocrinology,Dalian Hospital Shengjing Hospital Affiliated to China Medical University,Dalian 116600,China)
出处
《中国医药指南》
2022年第36期62-65,共4页
Guide of China Medicine